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Abstract Scheie syndrome is the most attenuated and
rarest form of mucopolysaccharidosis type I (MPS I), an
inherited lysosomal storage disorder. Only small patient
series have previously been reported. Using natural history
data from the uniquely large population of 78 Scheie
patients enrolled in the MPS I Registry, we characterized
the onset and prevalence of clinical manifestations and
explored reasons for delayed diagnosis of the disease.
Median patient age was 17.5 years; 46% of the patients
were male, and 88% were Caucasian. Of 25 MPS I-related
clinical features, cardiac valve abnormalities, joint contrac-
tures, and corneal clouding were each reported by >80%
and all three by 53% of patients. Carpal tunnel syndrome,
hernia, coarse facial features, and hepatomegaly were each
reported by >50% of patients. Age at onset of the clinical
features varied widely between individuals, but the median
age at onset was 3 years for hernia and between 5 and
12 years for most features, including coarse facial features,
hepatomegaly, joint contractures, bone deformities, cardiac
valve abnormalities, cognitive impairment, and corneal
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DOI 10.1007/s10545-010-9113-7clouding. Carpal tunnel syndrome, cardiomyopathy, and
myelopathy arose more commonly during adolescence or
adulthood. Delays up to 47 years intervened between
symptom onset and disease diagnosis, and the longest
delays were associated with later age at symptom onset and
symptom onset before 1980. In summary, Scheie syndrome
usually emerges during childhood, and recognition of
attenuated MPS I requires awareness of the multisystemic
disease manifestations and their diverse presentation. Given
the availability of etiologic treatment, prompt diagnosis is
important.
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Introduction
Timely recognition and accurate diagnosis of Scheie
syndrome, the attenuated form of mucopolysaccharidosis
type I (MPS I; OMIM#252800), have acquired greater
urgency with the advent of enzyme replacement therapy
(ERT) as an etiologic treatment option for this rare
lysosomal storage disorder (Clarke et al. 2009; Giugliani
et al. 2009; Kakkis et al. 2001; Wraith et al. 2004). MPS I
results from the autosomal recessive inheritance of a
deficiency of α-L-iduronidase (IDUA; EC 3.2.1.76), an
enzyme in the degradative pathway for two glycosamino-
glycans (GAG), heparan sulfate and dermatan sulfate,
which contribute to the structural and functional integrity
of most connective tissues. IDUA deficiency leads to
widespread GAG accumulation accompanied by deteriora-
tion of function in multiple organ systems (Neufeld and
Muenzer 2001). The most prominent and debilitating
manifestations usually arise in the musculoskeletal, cardio-
respiratory, and central nervous systems, but individual
patients vary considerably in the timing of symptom onset,
the pattern of organ involvement, and the rate of disease
progression. Three syndromes, broadly based on the
severity of clinical complications and age at presentation,
are used to categorize the heterogeneous MPS I pheno-
types. Patients expressing the most severe phenotype,
Hurler syndrome, rapidly develop conspicuous signs,
including characteristic facial dysmorphia and progressive
cognitive impairment, that lead to disease diagnosis within
the first 2 years of life. In contrast, patients with the most
attenuated phenotype, Scheie syndrome, manifest variable
and generally milder symptoms that may emerge over many
years, often delaying diagnosis. The third syndrome,
Hurler-Scheie, designates an intermediate phenotype and
underscores that MPS I spans a continuous disease
spectrum without clear lines of demarcation between the
three syndromes.
Due to its rarity, Scheie syndrome has been described in
small case series only, with patients selected on the basis of a
single clinical parameter or combined with other MPS I
phenotypes (Cimaz et al. 2006;S c h e i ee ta l .1962; Stevenson
et al. 1976; Vieira et al. 2008; Vijay and Wraith 2005). A
uniquely large Scheie population is now available for
analysis from the MPS I Registry (Pastores et al. 2007), a
global observational program for monitoring patients with
MPS I (www.mpsiregistry.com). Here we use natural history
data from 78 registry patients diagnosed with Scheie
syndrome to characterize the onset and prevalence of disease
manifestations and to explore reasons why diagnosis is often
delayed.
Methods
The MPS I Registry was established in 2003 for the long-
term observation of MPS I patients in compliance with
regulatory commitments upon marketing approval of ERT
with laronidase, a recombinant form of human IDUA
(Aldurazyme®; BioMarin Pharmaceutical Inc., Novato,
CA, USA, and Genzyme Corporation, Cambridge, MA,
USA). Any patient with a confirmed MPS I diagnosis can
be enrolled in the registry by a treating physician. Patient
authorization that complies with local and international
guidelines is obtained prior to enrollment. Registry data are
derived from responses to a detailed questionnaire for
monitoring MPS I-related clinical signs based on medical
history and ongoing assessments (Pastores et al. 2007).
Individual patient data remain confidential.
Analyses of MPS I Registry data collected from October
2003 to October 2008 were performed by Biomedical Data
Sciences and Informatics at Genzyme. A total of 759 patients
were enrolled, and syndrome diagnoses were provided by the
treating physician as follows: 78 (10.3%) with Scheie
syndrome, 292 (55.7%) with Hurler syndrome, and 180
(23.7%) with Hurler-Scheie syndrome; for the remaining
10.3%,a syndromedesignationwas undeterminedormissing.
For the analyses reported here, the study population consisted
of all patients with an entered diagnosis of Scheie syndrome.
The 78 patients with Scheie syndrome were enrolled by 38
physiciansfrom17countriesinNorth America, Europe,Latin
America, and Asia Pacific. Each physician enrolled between
one and eight patients, with two physicians enrolling seven
and eight patients, respectively. Only natural history data
[before ERT initiation or hematopoietic stem cell transplanta-
422 J Inherit Metab Dis (2010) 33:421–427tion (HSCT)] were evaluated for the Scheie cohort. Individ-
uals were excluded from an analysis if relevant entries were
missing or unknown. Patient numbers are stated for each
analysis, and descriptive statistics are presented. Pearson’s
correlation coefficients (r), computed to assess associations
between parameters, were considered statistically significant
if P values derived from t tests were <0.05.
Results
Patient population
Demographic data are presented in Table 1 for the 78
patients with Scheie syndrome enrolled in the MPS I
Registry. Diagnostic IDUA enzyme activity levels or IDUA
gene mutation(s) were reported for each patient, but initial
MPS I diagnoses were based on some combination of
clinical presentation (n=55), enzyme activity (n=48), and/
or gene mutations (n=5). A total of 24 patients reported
siblings with MPS I, but families were not linked in the
registry at the time of analysis. Two patients were enrolled
posthumously: a 23-year-old man who died of heart failure
and cor pulmonale, and a 17-year-old woman who died of
multiorgan failure and septicemia 11 days after mitral and
aortic valve replacement surgery.
Clinical features
Figure 1 demonstrates that 19 of the 25 clinical features
monitored in the registry arose during childhood in the
majority of patients, although wide variability was observed
between individual patients for each feature. Hernia was the
only feature with a median age at onset before 5 years, whereas
a median age at onset between 5 and 12 years was observed for
18 clinical features, mostly involving infiltration and enlarge-
ment of soft tissues or joint and bone complications. Scoliosis,
carpal tunnel syndrome, and congestive heart failure were more
likely to arise in adolescence; and glaucoma, cardiomyopathy,
a n dm y e l o p a t h yi ne a r l ya d u l t h o o d .B a s e do nt h eo n s e td a t e s
entered for the 25 clinical features, none emerged as a first sign
in a majority of patients. Hernia and joint contractures each
appeared as a first sign in approximately 30% of the 72 patients
with data, but hernia was more often reported as an isolated
finding at birth or within the first year of life, whereas joint
contractures usually appeared after age 2 and more often in
conjunction with other disease manifestations.
Themediannumberofclinicalfeaturesreportedperpatient
was seven (range 0–15). The five most prevalent were cardiac
valve abnormalities, joint contractures, corneal clouding,
carpal tunnel syndrome, and hernia (Fig. 2). All five features
were reported by 31.0% of patients; and four, three, two, or
one feature was reported, respectively, by 18.3%, 25.4%,
14.1%, or 5.6%. Only 5.6% reported none of the five.
Cardiac valve abnormalities were reported by 87.9% (58/
66) of patients at a median age of 11.7 years. Echocardio-
graphy data available for 50 patients showed abnormal
function of one valve in 40% and of two or more valves in
60%. The mitral and aortic valves were most commonly
affected (Table 2), with valve replacement surgery docu-
mented for 14% of the patients.
Joint contractures were reported in 87.7% (57/65) of
patients at a median age of 7.2 years. Joint contractures,
frequentlyobservedinconjunctionwithothermusculoskeletal
abnormalities,weredocumentedfor>90%ofpatientswithpes
cavus, genu valgum, and toe walking and by 84–87% of
patients with dysostosis multiplex, kyphosis gibbus, scoliosis,
and hip dysplasia. Among 71 patients reporting clinical
features, tendon release surgery was reported for 4%; hip,
knee, or foot surgery for 8%; and spine surgery for 4%.
Corneal clouding was reported by 81.8% (54/66) of
patients at a median age of 9.1 years. Results of slit-lamp
examinations available for 32 patients revealed that corneal
clouding occurred bilaterally in all patients and was of
equal severity in both eyes except in one patient. The
degree of clouding, considered mild in 78.1% (25/32) of
patients, did not correlate with age at assessment.
Carpaltunnel syndrome wasreportedby66.7%(44/66)of
patients at a median age of 13.1 years. Surgical interventions
were documented for 52.2% (23/44) of those affected.
Accompanying symptoms reported by 35 patients included
pain (71.4%), tingling (54.2%), numbness (51.4%), weak-
ness (34.3%), and burning sensation (20.0%).
Hernia was reported for 65.1% (41/63) of patients at a
median age of 3.3 years. Among 39 patients with data
Table 1 Demographic data for patients with Scheie syndrome
Parameter Value [n (%)]
Patients with Scheie syndrome 78
Alive 76 (97.4)
Deceased 2 (2.6)
Gender
Male 36 (46.2)
Female 42 (53.8)
Ethnicity
Caucasian 69 (88.5)
Black 2 (2.6)
Hispanic 1 (1.3)
Asian 1 (1.3)
Other 5 (6.4)
Age in years
Mean (standard deviation) 22.9 (13.6)
Median 17.5
Minimum, maximum 1.8, 62.9
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(87.2%) than left (30.8%) and right (25.6%) inguinal
hernias. The majority (66.7%) reported hernia in a single
location; 10.2% and 17.9% had hernias in two and three
locations, respectively. Herniorrhaphy was documented for
68.3% (28/41).
Diagnostic delays
For 71 patients with dates reported, age at first symptom
onset ranged from birth to 33.8 (median 5.4) years, and age
of MPS I diagnosis ranged from before birth to 54.1 (me-
dian 9.8) years. Two patients, both with MPS I siblings,
were diagnosed presymptomatically: one before birth and
one at age 5 years. The remaining 69 patients were
diagnosed after symptom onset, with delays of 0 to
47.2 (median 2.0) years from first symptom onset to
disease diagnosis. To explore differences in diagnostic
delays, the 69 patients were categorized by age at diagnosis
into four subgroups. Figure 3a demonstrates that the
median age at first symptom onset was younger than
10 years for all subgroups, but the range broadened as age
at diagnosis increased. The delay from first symptom onset
to disease diagnosis was longer and more variable as age at
diagnosis increased (Fig. 3a). The median number of
clinical features present at diagnosis did not differ among
subgroups (three for each subgroup diagnosed before age
20; five for the subgroup diagnosed after age 20), but
differences between subgroups were noted in the most
prevalent clinical features present at diagnosis (Fig. 3b).
Coarse facial features was reported by 63% of the subgroup
diagnosed before age 5 years compared with 21–31% of
Fig. 1 Age at onset of 25
clinical features of mucopoly-
saccharidosis type I (MPS I).
The symbol represents the
median; the bar shows the
range; n = the number of
patients with an onset date
reported
Fig. 2 Percentage of patients
with Scheie syndrome reporting
clinical features of mucopoly-
saccharidosis type 1 (MPS I).
Percentages, calculated from the
fractions shown in parentheses,
represent the number of patients
who entered “yes” divided by
the sum of those who entered
“yes” or “no” for the presence of
the clinical feature
424 J Inherit Metab Dis (2010) 33:421–427subgroups diagnosed after age 5 years. Joint contracture
was most prevalent in the subgroup diagnosed between 5
and 10 years of age, and dysostosis multiplex and cardiac
valve abnormalities were most common in the subgroup
diagnosed after age 20 years. Figure 3c indicates that
clinical manifestations tended to arise earlier in patients
diagnosed at younger ages and later in patients diagnosed at
older ages. There were strong, statistically significant
correlations between age at diagnosis and age at onset
for all clinical features presented in Fig. 3c (r=0.73–
0.98; P≤0.001), except hernia (r=0.47; P=0.17).
Figure 3d displays the length of diagnostic delays as a
function of the calendar year in which symptoms were
first noted. Patients with the longest diagnostic delays had
first symptom onset before 1980.
Discussion
Natural history data were reviewed for 78 patients with
Scheie syndrome, representing the largest cohort with this
rare genetic disorder examined to date. Strikingly, the
pattern of disease progression indicates that most clinical
features associated with MPS I first appeared before the age
of 12 years in the majority of patients. Among individuals,
the first clinical feature(s) to emerge varied, but the most
common first sign to appear before age 2 years was hernia
and after age 2 years joint contractures. Some early signs,
such as hernias and enlarged tonsils, are relatively common
in the general pediatric population and in isolation would
not raise suspicion for MPS I. More indicative of MPS I are
the flexion contractures, especially of the fingers and hands,
that children with Scheie syndrome often develop. In MPS
I, joint pain, stiffness, and immobility are not accompanied
by inflammation, as in some other rheumatological con-
Table 2 Cardiac valve abnormalities detected by echocardiography in
patients with Scheie syndrome
Total number of patients evaluated: 50
Stenosis
[% (n)]
Regurgitation
[% (n)]
Prolapse
[% (n)]
Any
[% (n)]
Mitral valve 32 (16) 76 (38) 16 (8) 78 (39)
Aortic valve 36 (18) 56 (28) n/a 66 (33)
Tricuspid valve 0 24 (12) n/a 24 (12)
Pulmonary valve 4 (2) 8 (4) n/a 12 (6)
n/a not applicable
Fig. 3 Analyses to explore diagnostic delays. a Age at first symptom
onset (upper box plot) and the interval from first symptom onset to
diagnosis (lower box plot) for patients categorized by age at diagnosis
(see y-axis). Data shown are the median (gap within box), 25th and
75th percentiles (left and right sides of box, respectively), and range
(line extending from box). b The most prevalent clinical features
reported before diagnosis in patients categorized by age at diagnosis. c
Age at onset of most prevalent clinical features in patients categorized
by age at diagnosis. Symbols represent medians; lines represent
ranges. d Trends in diagnosis over time in patients categorized by
age at diagnosis. Each symbol represents a patient
J Inherit Metab Dis (2010) 33:421–427 425ditions that arise in childhood (Cimaz et al. 2006). The
wide variability observed in the age at onset for each
clinical feature underscores the heterogeneity of Scheie
syndrome, with disease pathology emerging in individual
patients at different times in different organs. While there is
no typical clinical profile for the Scheie phenotype, cardiac
valve abnormalities, joint contractures, and corneal cloud-
ing were each reported by >80% of patients. Only 7% had
none of these signs, whereas 53% reported all three. In
1962, Dr. Harold Scheie, an ophthalmologist, provided the
first biochemical evidence linking the corneal haze he
observed in ten patients to an attenuated forme fruste of
Hurler syndrome (Scheie et al. 1962). Flexion contractures
and heart murmurs were frequently noted among his
patients. Recent reports emphasize that children and adults
with Scheie syndrome most often present with rheumato-
logical symptoms, usually accompanied by ocular and
cardiac valve pathology (Cimaz et al. 2006; Vieira et al.
2008; Vijay and Wraith 2005). In addition to the triad of
joint, cardiac valve, and corneal abnormalities, the majority
of the registry patient cohort reported carpal tunnel
syndrome, hernia, coarse facial features, and hepatomegaly.
Chronic ear, nose, and throat and respiratory problems,
including sleep apnea and recurrent otitis media, also have
been noted in patients (Vijay and Wraith 2005; Wraith
2005). Furthermore, MPS I patients commonly require
multiple, often unrelated, surgical interventions, and 40%
of children with Scheie syndrome reported two or more
surgeries by 10 years of age (Arn et al. 2009).
Following the onset of signs and symptoms, MPS I
diagnosis was established for the registry patients with
Scheie syndrome between infancy and the sixth decade.
Analyses performed to explore this broad range suggested
that patients diagnosed early express phenotypes that are
more pronounced and that evolve more rapidly than
patients diagnosed later. Prior to diagnosis, the facial
dysmorphia that is characteristic of MPS I appeared in
almost two thirds—and joint contractures in more than
half—of the patients diagnosed before age 5 years. Among
patients diagnosed after age 5, joint contractures occurred
in the majority, but less than one third displayed coarse
facial features before diagnosis. Patients diagnosed after
age 20 years had, on average, slightly more clinical signs of
MPS I at the time of diagnosis than patients diagnosed
earlier, but no feature predominated as in the subgroups
diagnosed earlier. For most clinical features, strong corre-
lations were found between the age at which the feature
was reported and the age at which the patient was
diagnosed. Taken together, these observations suggest that
MPS I manifestations emerged more slowly and variably in
patients diagnosed after the age of 20 years. Yet, it is also
noteworthy that the number of patients diagnosed has
increased annually since 1962, when Scheie syndrome was
first described, most likely mirroring a growing awareness
of the attenuated phenotype. For the registry patients with
Scheie syndrome born before 1970 and diagnosed in
adulthood despite symptom onset in childhood, the lack
of disease awareness is most likely responsible for the
delayed diagnosis.
The limitations in interpreting the data presented here
begin with the diagnosis of Scheie syndrome. MPS I spans
a continuum of disease, and the three syndromes are not
rigorously defined and cannot currently be distinguished by
biochemical criteria or genotype in most cases. Hence,
syndrome designation depends on the clinical judgment of
the reporting physician. Subgroup analyses presented in
Fig. 3 emphasize the likelihood that some registry patients
express phenotypes that border the intermediate, Hurler-
Scheie part of the disease spectrum. Indeed, two patients
who were diagnosed before 18 months of age had coarse
facial features and cognitive impairment present at diagno-
sis. Although early onset of these manifestations is more
typical of Hurler or Hurler-Scheie syndromes, data are
included from one patient up to 10.3 years of age when
ERT was initiated and for the other up to 1.8 years of age
when HSCT was performed. Another limitation of the
reported data stems from the fact that MPS I is rare, and the
attenuated phenotype is the rarest form of the disease
(Meikle et al. 1999; Neufeld and Muenzer 2001). Even
though the registry cohort is the largest examined thus far,
the sample size is relatively small. Finally, limitations
associated with any voluntary, observational disease regis-
try must be considered, including selection bias, reporting
bias, and unverified data entries (Pastores et al. 2007).
Clinical management of patients with Scheie syndrome
requires an individualized approach best coordinated by a
multidisciplinary team (Muenzer et al. 2009). ERT is
approved in more than 55 countries worldwide for
treatment of the non-neurological manifestations of MPS
I. A phase 3 extension trial demonstrated stabilization or
improvement of several clinical parameters in Scheie and
Hurler-Scheie patients after approximately 4 years of ERT
(Clarke et al. 2009). Improvement of cardiomyopathy with
ERT has been reported, but cardiac valve disease appears to
be less responsive, possibly because the treatment period
was too short or because treatment was initiated late in the
disease process (Braunlin et al. 2006). A recent case report
of two siblings with Hurler-Scheie syndrome who began
ERT at 5 months and 5 years of age, respectively, suggests
that many MPS I disease manifestations, including cardiac
valve disease, can be prevented if ERT is begun at an early
age, but only partially reversed or stabilized if begun at a
later age (Gabrielli et al. 2009). Thus, ERT is expected to
provide the greatest clinical benefit when initiated before
permanent tissue damage has ensued and attention has been
drawn to patients with Scheie syndrome whose disease may
426 J Inherit Metab Dis (2010) 33:421–427not be recognized. Timely disease recognition also provides
potential benefits with regard to genetic counseling for
families and more timely interventions for patients, which,
in turn, may produce better outcomes, slow disease
progression, and/or improve quality of life. As reported
here, clinical signs usually emerge during childhood in the
attenuated phenotype, and prompt diagnosis requires
awareness of the multisystemic manifestations and diverse
presentation of MPS I.
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